This site is intended for healthcare professionals only
LoginRegister
Boehringer Ingelheim, LEO Pharma collaborateAurobindo Pharma Partners with Global Pharma Major for Respiratory Product Development
D Pharm Studens Unlicensed Store Busted in Haryana, ACB Arrests Drug Official During RaidRaid: Telangana DCA Seizes Cefuroxime, Dexamethasone, Other Antibiotics, Steroids from Unlicensed...
Spurious DrugsHimachal HC Orders Investigation into Spurious Drugs Production at Baddi Pharma Units
Novartis ianalumab Phase III trial meets primary endpoint in immune thrombocytopeniaNovartis Healthcare gets CDSCO Panel nod to study Iptacopan
Zydus Asked to Revise Phase III Trial Protocol for Cough Syrup FDC After CDSCO Panel ReviewConduct Phase III CT: CDSCO Panel Tells Zydus Healthcare on Glycopyrrolatem plus Indacaterol...
Abbott Gets SEC Nod to Market Chlordiazepoxide Tablets for Anxiety, Alcohol WithdrawalAbbott's Plea Alleging NPPA Used Outdated PTR Data for Metoprolol Pricing Rejected by DoP
Eli Lilly Collaborates with Laekna to Develop Obesity Drug Targeting Muscle Preservation and Weight LossEli Lilly Collaborates with Laekna to Develop Obesity Drug Targeting Muscle Preservation and Weight...
Novartis Told to Revise Protocol, Justify Sample Size in ITU512 Clinical Trial ProposalDespite Pluvicto, MorphoSys Setbacks, Novartis Raises 2028 Sales Growth Outlook to 6%
Like USFDA, we need Bharat Food and Drug Administration for global benchmarks, says FM SitharamanLike USFDA, we need Bharat Food and Drug Administration for global benchmarks, says FM Sitharaman
MSN Labs Gets CDSCO Panel Nod to Begin Phase III Trial of Cenobamate Tablets, With Safety CaveatMSN Laboratories Gets CDSCO Panel nod to Manufacture, Market Tolvaptan Tablets 7.5 mg
Lupin unveils Glucagon for Injection for severe hypoglycemia in patients with diabetes mellitus in USRevise protocol for Denosumab 60 mg prefilled syringe solution for injection: CDSCO Panel tells...
No More Physical WHO-GMP Certificate Applications After August 15: DCGI Alerts Pharma FirmsDCGI Warns Cosmetic Industry Against Overlapping Claims With Pharma Products
X